Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer-Reference-Cited by-同舟云学术

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Published:2017-12-13 Issue:2 Volume:17 Page:464-473
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Huang Yan,Hu Wei,Huang Jie,Shen Fangrong,Sun Yunjie,Ivan Cristina,Pradeep Sunila,Dood Robert,Haemmerle Monika,Jiang Dahai,Mangala Lingegowda S.,Noh Kyunghee,Hansen Jean M.,Dalton Heather J.,Previs Rebecca A.,Nagaraja Archana S.,McGuire Michael,Jennings Nicholas B.,Broaddus Russell,Coleman Robert L.,Sood Anil K.

Funder

HHS | NIH | National Cancer Institute (NCI)

Arno Therapeutics Inc.

The Frank McGraw Memorial Chair in Cancer Research

The Ann Rife Cox Chair in Gynecology

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer;Gynecologic Oncology;2024-10

2. Unexplored Functions of Sex Hormones in Glioblastoma Cancer Stem Cells;Endocrinology;2022-01-12

3. Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: Elucidating Molecular Mechanisms and Clinical Significance;Frontiers in Oncology;2020-09-04

4. The Therapeutic Potential of MEK1/2 Inhibitors in the Treatment of Gynecological Cancers: Rational Strategies and Recent Progress;Current Cancer Drug Targets;2020-07-07

5. Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate;Clinical Cancer Research;2019-09-30